The objective of this study was to assess the pharmacodynamics of ipragliflozin in T2DM patients with impaired renal function ... Because SGLT2 inhibitors act on the kidney, and the amount ...

While SGLT2 inhibitors have been included in international treatment guidelines for people with diabetes and CKD since 2018, only around 7% of these patients in the US are receiving these ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, cardiovascular disease and overall mortality are well known. Now ...

“Our study suggests that SGLT2 inhibitors may provide benefit in slowing the progression of kidney disease, particularly within a high-risk population like Asians, who are known to have ...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD).

To TCTMD, Wiviott said there is a large body of evidence supporting the SGLT2 inhibitor drug class, noting the medications have been a “remarkable advance in diabetes management and the prevention and ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.